Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | TAF1 | P21675 | 1/20 | 0.32 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22456351 | 0.89 | L3MBTL3 (0.34) | L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL803511 | 0.88 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1HRH3BRD4TAF1 | |
| SCHEMBL26170496 | 0.85 | HRH3 (0.34) | L3MBTL3L3MBTL1HRH3TLR9TLR8 | |
| SCHEMBL13860740 | 0.85 | HRH3 (0.33) | L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL23384260 | 0.81 | HRH3 (0.40) | L3MBTL3L3MBTL1HRH3TLR9TLR8 | |
| SCHEMBL24726517 | 0.81 | HRH3 (0.40) | L3MBTL3L3MBTL1HRH3TLR9TLR8 | |
| SCHEMBL23339319 | 0.80 | L3MBTL3 (0.34) | L3MBTL3L3MBTL1HRH3BRD4TAF1 | |
| SCHEMBL22456342 | 0.79 | HRH3 (0.41) | L3MBTL3L3MBTL1HRH3TLR9TLR8 | |
| SCHEMBL14453902 | 0.79 | HRH3 (0.41) | L3MBTL3L3MBTL1HRH3TLR9TLR8 | |
| SCHEMBL26170570 | 0.79 | BRD4 (0.40) | L3MBTL3L3MBTL1HRH3BRD4TAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2021216440-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3715350-A1 | ARYLPHOSPHINE OXIDES FOR INHIBITING KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2020-09-30 | — | — | EP | disclosed |
| WO-2020190119-A1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | 주식회사 보로노이 | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | ERBB2, ALK, ERBB3 | L3MBTL3 3062/4885L3MBTL1 2421/4885HRH3 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.